Organogenesis Inks Full-Building Lease with the Davis Companies in Rhode Island
The Davis Companies has secured a full-building lease agreement for 100 Technology Way in Smithfield, Rhode Island, with Organogenesis Holdings Inc., a leading regenerative medicine company. The property is a 123,000-square-foot biomanufacturing facility. Specific lease terms were not disclosed.
“In a competitive manufacturing and life sciences market, our lease agreement with Organogenesis demonstrates Davis’ commitment to providing premier tenant experiences in locations that best allow businesses to innovate and scale,” said Jon Needham, Senior Vice President of Asset Management at The Davis Companies. “We are thrilled to welcome Organogenesis to the building and to support their growth plans as the company leads in the biomanufacturing sector and enhances Rhode Island’s and greater New England’s innovation ecosystem.”
A multi-year construction initiative is now underway to upgrade the facility’s capabilities as a current Good Manufacturing Practice (cGMP) site. Designed with substantial utility infrastructure, the building is well-positioned to support Organogenesis’ specialized manufacturing operations.
Organogenesis was represented in the deal by Robert Coughlin and Bobby Jangro of JLL. Mark Winters and Tyler McGrail of Newmark represented The Davis Companies and the property.
